Eyenovia, Inc.
(NASDAQ : EYEN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -3.11%35.490.9%$903.44m
JNJJohnson & Johnson -3.10%144.560.7%$900.44m
MRKMerck & Co., Inc. -4.01%82.370.7%$680.57m
ABBVAbbVie, Inc. -3.01%87.401.9%$643.31m
BMYBristol-Myers Squibb Co. -3.27%57.341.0%$551.59m
LLYEli Lilly & Co. -2.50%150.321.1%$538.24m
AZNAstraZeneca Plc -2.37%55.111.2%$247.04m
NVSNovartis AG -2.33%88.820.2%$162.62m
PRNBPrincipia Biopharma, Inc. -0.31%99.960.0%$117.69m
GSKGlaxoSmithKline Plc -3.03%38.070.2%$97.47m
CVACCureVac NV -5.45%49.250.0%$68.80m
NVONovo Nordisk A/S -1.74%68.230.1%$53.30m
RGENRepligen Corp. -4.75%139.057.1%$51.85m
OPKOPKO Health, Inc. 0.32%3.1811.2%$47.39m
SNYSanofi -4.10%50.290.2%$47.04m

Company Profile

Eyenovia, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of ophthalmology products. The company offers a piezo-print technology to deliver micro-doses of micro-therapeutics for the eyes. Its products include MicroProst, MicroStat, MicroTears, and MicroPine. The firm is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. The company was founded by Sean Ianchulev on March 12, 2014 and is headquartered in New York, NY.